Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer — ExOnSite-Pro  

Lung Cancer Clinical Trial

Official title: Analyse du Profil moléculaire Des Exosomes de la Veine Pulmonaire Dans le Cancer Bronchique de Stade précoce

Status Active, not recruiting

Clinical Trial Summary

This is an observational prospective single-center study of 30 patients operated for early-staged non-small cell lung cancer. The main aim is the analysis of molecular profiling of exosome with a sample in tumor-draining vein in order to identify prognostic molecular characteristics associated with cancer recurrence after surgery.

Clinical Trial Description

Surgical resection remains the best chance for cure in patients with early-stage non-small-cell lung cancer (NSCLC). Unfortunately, approximately 30-50% of patients will relapse within 5-year of curative surgery despite early TNM-stage. The Identification of prognostic biomarkers of relapse is a necessity. Among them, extracellular vesicles (exosomes) study seems promising in early stage cancers and samples directly in tumor-draining vein to. The pulmonary vein is draining blood directly from the lungs and sampling at this location could provide a higher yield for oncosome. The litterature reports that Navarro et al. are the only team to have link exosome characteristics to oncological outcomes following surgery. The investigators propose to analyze the molecular profiling mediated by these extracellular vesicles in the tumor-draining vein of operated patients. A peripheral blood sample is recolted before surgery (D-1 or D0). During oncological lung surgery, the pulmonary tumor-drainage vein is first exposed and punctured with a needle prior to subsequent surgical manipulation for resection (D0). A piece of resected tumor will be analyzed for the study (D0). Quantification and size distribution of exosome and molecular cargo of exosome in blood samples (peripheral and pulmonary vein) and tumor are analyzed (DNA sequencing). Standard clinical and radiological follow-up is then performed and 2-year overall survival and 2-year disease free-survival are checked. ;

Related Conditions & MeSH terms

• Exosomes
• Lung Cancer
• Lung Neoplasms
• Non Small Cell Lung Cancer

• NCT number: NCT04939324
• Study type: Interventional
• Source: University Hospital, Limoges
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 21, 2021
• Completion date: June 6, 2024